Logo
x

Search

Subscribe Now

Priority Review

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin...

  • November 12, 2021
Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

  • November 12, 2021
Novartis Reports the US FDA and EMA's Acceptance of sBLA for Kymriah (tisagenlecleucel) and Granted Priority Review to Treat R/R Follicular Lymphoma

Novartis Reports the US FDA and EMA's Acceptance of sBLA for Kymriah (tisagenlecleucel) and Granted Priority Review to Treat R/R F...

  • October 29, 2021
Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

Regeneron Reports the US FDA's Acceptance of Priority Review for REGEN-COV for the Treatment and Prophylaxis of COVID-19

  • October 14, 2021
Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

  • August 18, 2021
Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

Merck Reports the US FDA's Acceptance of sBLA and Priority Review for Keytruda (pembrolizumab) as an Adjuvant Treatment for RCC

  • August 10, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.